NASDAQ:RGNX

REGENXBIO (RGNX) Stock Forecast, Price & News

$18.20

-0.06 (-0.33%)

(As of 05/26/2023 04:00 PM ET)

Compare

Today's Range: $17.89
▼
$18.47
50-Day Range: $17.26
▼
$21.71
52-Week Range: $17.03
▼
$35.73

Volume: 348,700 shs
Average Volume: 412,313 shs
Market Capitalization: $791.08 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $40.00

REGENXBIO MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.67 Rating Score
Upside/Downside: 119.8% Upside
$40.00 Price Target
Short Interest: Bearish
12.32% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.82
Upright™ Environmental Score
News Sentiment: 1.03
Based on 8 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($4.31) to ($2.46) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.11 out of 5 stars

Medical Sector

528th out of 1,010 stocks

Biological Products, Except Diagnostic Industry

80th out of 169 stocks

3.3

Analyst's Opinion

Consensus Rating
REGENXBIO has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 4 buy ratings, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $40.00, REGENXBIO has a forecasted upside of 119.8% from its current price of $18.20.
Amount of Analyst Coverage
REGENXBIO has only been the subject of 2 research reports in the past 90 days.

0.0

Short Interest

Percentage of Shares Shorted
12.32% of the float of REGENXBIO has been sold short.
Short Interest Ratio / Days to Cover
REGENXBIO has a short interest ratio ("days to cover") of 10.9, which indicates bearish sentiment.
Change versus previous month
Short interest in REGENXBIO has recently increased by 2.53%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
REGENXBIO does not currently pay a dividend.
Dividend Growth
REGENXBIO does not have a long track record of dividend growth.

4.6

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
REGENXBIO has received a 71.89% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is mostly driven by its "Clinical research services for genetic diseases", "Clinical research services for physiological diseases ", and "Basic medical research services" products. See details.
Environmental Sustainability
The Environmental Impact score for REGENXBIO is -0.82.

2.8

News and Social Media Coverage

News Sentiment
REGENXBIO has a news sentiment score of 1.03. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.77 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 8 news articles for REGENXBIO this week, compared to 3 articles on an average week.
MarketBeat Follows
Only 1 people have added REGENXBIO to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, REGENXBIO insiders have not sold or bought any company stock.
Percentage Held by Insiders
12.70% of the stock of REGENXBIO is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
80.21% of the stock of REGENXBIO is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for REGENXBIO are expected to grow in the coming year, from ($4.31) to ($2.46) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of REGENXBIO is -2.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of REGENXBIO is -2.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
REGENXBIO has a P/B Ratio of 1.53. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About REGENXBIO (NASDAQ:RGNX) Stock

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Receive RGNX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for REGENXBIO and its competitors with MarketBeat's FREE daily newsletter.

RGNX Stock News Headlines

May 27, 2023 | americanbankingnews.com

REGENXBIO (NASDAQ:RGNX) Shares Down 7.5%

May 23, 2023 | seekingalpha.com

Regenxbio's gene therapy for Hunter syndrome gets FDA regenerative medicine status

May 29, 2023 | Behind the Markets (Ad)

Laser breakthrough could send stock soaring 2,467%

Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...

May 23, 2023 | finance.yahoo.com

REGENXBIO Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RGX-121 Gene Therapy for Hunter Syndrome

May 22, 2023 | americanbankingnews.com

StockNews.com Initiates Coverage on REGENXBIO (NASDAQ:RGNX)

May 22, 2023 | americanbankingnews.com

REGENXBIO Inc. (NASDAQ:RGNX) Receives $40.00 Consensus Target Price from Analysts

May 17, 2023 | americanbankingnews.com

REGENXBIO (NASDAQ:RGNX) Shares Up 8.8%

May 16, 2023 | finance.yahoo.com

REGENXBIO Announces NAV® Technology Platform Will Support Bespoke Gene Therapy Consortium's First Rare Disease Clinical Portfolio

May 29, 2023 | Behind the Markets (Ad)

[BREAKING] New "Living Missile" to Replace Nuclear Missiles

CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!

May 12, 2023 | msn.com

Regenxbio: Buy, High-Potential Stock Stagnant Due To No Near-Term Catalysts

May 12, 2023 | msn.com

Regenxbio's Return On Capital Employed Insights

May 10, 2023 | markets.businessinsider.com

Analyst Expectations for Regenxbio's Future

May 10, 2023 | msn.com

Morgan Stanley Maintains Regenxbio (RGNX) Overweight Recommendation

May 8, 2023 | americanbankingnews.com

REGENXBIO (NASDAQ:RGNX) PT Lowered to $55.00

May 7, 2023 | americanbankingnews.com

REGENXBIO (NASDAQ:RGNX) Stock Price Down 5.8% Following Analyst Downgrade

May 6, 2023 | americanbankingnews.com

REGENXBIO (NASDAQ:RGNX) Shares Gap Down After Earnings Miss

May 5, 2023 | americanbankingnews.com

REGENXBIO (NASDAQ:RGNX) Posts Quarterly Earnings Results, Misses Expectations By $0.01 EPS

May 3, 2023 | finance.yahoo.com

REGENXBIO Reports First Quarter 2023 Financial Results and Recent Operational Highlights

May 2, 2023 | finance.yahoo.com

REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 26th Annual Meeting

May 1, 2023 | americanbankingnews.com

REGENXBIO (RGNX) Scheduled to Post Quarterly Earnings on Wednesday

April 26, 2023 | finance.yahoo.com

REGENXBIO to Host Conference Call on May 3 to Discuss First Quarter 2023 Financial Results and Recent Operational Highlights

April 25, 2023 | americanbankingnews.com

REGENXBIO Inc. (NASDAQ:RGNX) Receives $40.86 Consensus Price Target from Analysts

April 18, 2023 | finance.yahoo.com

REGENXBIO Announces Presentation at Chardan's 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit

April 15, 2023 | americanbankingnews.com

Head-To-Head Survey: Vaxart (NASDAQ:VXRT) versus REGENXBIO (NASDAQ:RGNX)

April 12, 2023 | markets.businessinsider.com

REGENXBIO: FDA Grants Fast Track Designation For RGX-202

April 12, 2023 | americanbankingnews.com

REGENXBIO (NASDAQ:RGNX) Shares Down 6.6%

April 11, 2023 | finance.yahoo.com

REGENXBIO Receives FDA Fast Track Designation for RGX-202, a Novel Gene Therapy Candidate for the Treatment of Duchenne Muscular Dystrophy

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive RGNX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for REGENXBIO and its competitors with MarketBeat's FREE daily newsletter.

RGNX Company Calendar

Last Earnings: 5/03/2023
Today: 5/29/2023
Next Earnings (Estimated): 8/02/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:RGNX
CUSIP: N/A
CIK: 1590877
Web: www.regenxbio.com
Phone: (240) 552-8181
Fax: N/A
Employees: 372
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $40.00
High Stock Price Forecast: $61.00
Low Stock Price Forecast: $14.00
Forecasted Upside/Downside: +119.8%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.67
Research Coverage: 6 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($6.24)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-280,320,000.00
Net Margins: -246.50%
Pretax Margin: -246.54%
Return on Equity: -49.69%
Return on Assets: -31.63%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 3.46
Quick Ratio: 3.46

Sales & Book Value

Annual Sales: $109.64 million
Price / Sales: 7.21
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $11.92 per share
Price / Book: 1.53

Miscellaneous

Outstanding Shares: 43,466,000
Free Float: 37,555,000
Market Cap: $791.08 million
Optionable: Optionable
Beta: 1.08

Key Executives

Kenneth T. Mills
President, Chief Executive Officer & Director

Curran M. Simpson
Chief Operating Officer

Vit Vasista
Chief Financial Officer & Senior Vice President

Jerome W. Jackson
Vice President-Information Technology

Olivier Danos
Chief Scientific Officer & Senior Vice President

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

RGNX Stock - Frequently Asked Questions

Should I buy or sell REGENXBIO stock right now?: 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for REGENXBIO in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" RGNX shares.
View RGNX analyst ratings or view top-rated stocks.
What is REGENXBIO's stock price forecast for 2023?: 6 Wall Street research analysts have issued 1-year price targets for REGENXBIO's stock. Their RGNX share price forecasts range from $14.00 to $61.00. On average, they anticipate the company's share price to reach $40.00 in the next twelve months. This suggests a possible upside of 119.8% from the stock's current price.
View analysts price targets for RGNX or view top-rated stocks among Wall Street analysts.
How have RGNX shares performed in 2023?: REGENXBIO's stock was trading at $22.68 at the beginning of 2023. Since then, RGNX stock has decreased by 19.8% and is now trading at $18.20.
View the best growth stocks for 2023 here.
When is REGENXBIO's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 2nd 2023.
View our RGNX earnings forecast.
How were REGENXBIO's earnings last quarter?: REGENXBIO Inc. (NASDAQ:RGNX) released its quarterly earnings results on Wednesday, May, 3rd. The biotechnology company reported ($1.53) earnings per share for the quarter, missing the consensus estimate of ($1.52) by $0.01. The biotechnology company earned $19.10 million during the quarter, compared to the consensus estimate of $31.29 million. REGENXBIO had a negative net margin of 246.50% and a negative trailing twelve-month return on equity of 49.69%. The company's revenue for the quarter was down 14.0% compared to the same quarter last year. During the same period in the previous year, the firm earned ($1.62) earnings per share.
What ETFs hold REGENXBIO's stock?: ETFs with the largest weight of REGENXBIO (NASDAQ:RGNX) stock in their portfolio include Invesco Dynamic Biotechnology & Genome ETF (PBE), Global X Genomics & Biotechnology ETF (GNOM), WisdomTree BioRevolution Fund (WDNA), ETC 6 Meridian Small Cap Equity ETF (SIXS), Invesco S&P SmallCap 600 Pure Growth ETF (RZG), Virtus LifeSci Biotech Clinical Trials ETF (BBC), Invesco S&P SmallCap Health Care ETF (PSCH) and Invesco Raymond James SB-1 Equity ETF (RYJ).
What is Ken Mills' approval rating as REGENXBIO's CEO?: 3 employees have rated REGENXBIO Chief Executive Officer Ken Mills on Glassdoor.com. Ken Mills has an approval rating of 68% among the company's employees.

What other stocks do shareholders of REGENXBIO own?: Based on aggregate information from My MarketBeat watchlists, some companies that other REGENXBIO investors own include AbbVie (ABBV), Micron Technology (MU), NVIDIA (NVDA), Voyager Therapeutics (VYGR), Amarin (AMRN), CRISPR Therapeutics (CRSP), Pfizer (PFE), QUALCOMM (QCOM), Gilead Sciences (GILD) and Block (SQ).
What is REGENXBIO's stock symbol?: REGENXBIO trades on the NASDAQ under the ticker symbol "RGNX."
Who are REGENXBIO's major shareholders?: REGENXBIO's stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (18.50%), JPMorgan Chase & Co. (9.21%), State Street Corp (5.94%), Dimensional Fund Advisors LP (3.53%), Geode Capital Management LLC (1.75%) and First Manhattan CO. LLC. (1.03%). Insiders that own company stock include Allan M Fox, Curran Simpson, Kenneth T Mills, Kenneth T Mills, Patrick J Christmas, Steve Pakola, Vittal Vasista and WR Stephens, Iii 2012 Trust.
View institutional ownership trends.
How do I buy shares of REGENXBIO?: Shares of RGNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is REGENXBIO's stock price today?: One share of RGNX stock can currently be purchased for approximately $18.20.
How much money does REGENXBIO make?: REGENXBIO (NASDAQ:RGNX) has a market capitalization of $791.08 million and generates $109.64 million in revenue each year. The biotechnology company earns $-280,320,000.00 in net income (profit) each year or ($6.24) on an earnings per share basis.
How many employees does REGENXBIO have?: The company employs 372 workers across the globe.
How can I contact REGENXBIO?: REGENXBIO's mailing address is 9600 BLACKWELL ROAD SUITE 210, ROCKVILLE MD, 20850. The official website for the company is www.regenxbio.com. The biotechnology company can be reached via phone at (240) 552-8181 or via email at ir@regenxbio.com.

This page (NASDAQ:RGNX) was last updated on 5/29/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial